Watermeadow Medical, an Ashfield company

watermeadow.com

Watermeadow's scientific, clinical, industry and journal experience spans almost every therapy area and a diverse international client base. Our work with both international and specialist companies of all sizes pays tribute to the breadth of experience we offer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

RECRO ANNOUNCES ACQUISITION OF SAN DIEGO-BASED IRISYS, CREATING BI-COASTAL, FULL SERVICE CDMO

Recro Pharma, Inc. | August 16, 2021

news image

Recro Pharma, Inc. a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. Recro acquired IRISYS for approximately $50 million in a combination of cash, shares of Recro common stock and a seller promissory note. With its acquisition of IRI...

Read More

Business Insights, PHARMA TECH

TONIX PHARMACEUTICALS TO OBTAIN AN EXCLUSIVE LICENSE FROM COLUMBIA UNIVERSITY

Tonix Pharmaceuticals | February 14, 2023

news image

On February 13, 2023, Tonix Pharmaceuticals, a leading clinical-stage biopharmaceutical firm, announced that it has exercised an option to acquire an exclusive license from Columbia University to develop a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the prophylaxis or treatment of SARS-CoV-2 infection. COVID-19 is caused by SARS-CoV-2. Tonix Pharmaceuticals and Columbia University announced a research collaboration and option agreement in 2020...

Read More

Business Insights

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY’S PROPRIETARY

Globenewswire | May 09, 2023

news image

Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...

Read More

PHARMA TECH

FRONTAGE LABORATORIES ACQUIRES ACCELERA S.R.L.'S BIOANALYTICAL AND DMPK BUSINESSES

PR Newswire | January 03, 2024

news image

Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...

Read More
news image

Business Insights

RECRO ANNOUNCES ACQUISITION OF SAN DIEGO-BASED IRISYS, CREATING BI-COASTAL, FULL SERVICE CDMO

Recro Pharma, Inc. | August 16, 2021

Recro Pharma, Inc. a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. Recro acquired IRISYS for approximately $50 million in a combination of cash, shares of Recro common stock and a seller promissory note. With its acquisition of IRI...

Read More
news image

Business Insights, PHARMA TECH

TONIX PHARMACEUTICALS TO OBTAIN AN EXCLUSIVE LICENSE FROM COLUMBIA UNIVERSITY

Tonix Pharmaceuticals | February 14, 2023

On February 13, 2023, Tonix Pharmaceuticals, a leading clinical-stage biopharmaceutical firm, announced that it has exercised an option to acquire an exclusive license from Columbia University to develop a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the prophylaxis or treatment of SARS-CoV-2 infection. COVID-19 is caused by SARS-CoV-2. Tonix Pharmaceuticals and Columbia University announced a research collaboration and option agreement in 2020...

Read More
news image

Business Insights

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY’S PROPRIETARY

Globenewswire | May 09, 2023

Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...

Read More
news image

PHARMA TECH

FRONTAGE LABORATORIES ACQUIRES ACCELERA S.R.L.'S BIOANALYTICAL AND DMPK BUSINESSES

PR Newswire | January 03, 2024

Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us